Progress toward an eventual HIV vaccine
Source : https://www.nih.gov/news-events/nih-research-matters/progress-toward-eventual-hiv-vaccine
An experimental HIV vaccine elicited broadly neutralizing antibody precursors in people. With further development, the approach could lead to an effective vaccine strategy for HIV and AIDS. More than 1...
Conclusions/Relevance: These findings establish proof of concept and a crucial first step for the strategy of eliciting bnAbs against HIV. But this priming vaccine alone cannot induce production of mature bnAbs. Booster vaccines will be needed to elicit bnAb production and protection against HIV. The results support further development of such...
Impact of antenatal antiretroviral drug exposure on the growth of children who are HIV-exposed uninfected: the national South African Prevention of Mother to Child Evaluation cohort study - BMC Infectious Diseases
Source : https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-022-07847-9
Background The relationship between in-utero antiretroviral (ARV) drug exposure and child growth needs further study as current data provide mixed messages. We compared postnatal growth in the first 18-months of...
Conclusion: Findings provide evidence for initiating all pregnant women living with HIV on ART as fetal exposure had no demonstrable adverse effects on postnatal growth. Several non-HIV-related maternal, child and socio-demographic factors were independently associated with growth, highlighting the need for multi-sectoral interventions....
A systematic review and meta-analysis assessing antiretroviral therapy for treatment-experienced HIV adult patients using an optimized background therapy approach: is there evidence enough for a standardized third-line strategy? - Systematic Reviews
Source : https://systematicreviewsjournal.biomedcentral.com/articles/10.1186/s13643-022-02102-3
Background The World Health Organization (WHO) has identified the need for evidence on third-line antiretroviral therapy (ART) for adults living with HIV/AIDS, given that some controversy remains as to the...
Conclusions: Efficacy results demonstrated that the groups of HIV-experienced patients receiving the new ARV OBT were more likely to achieve viral suppression when compared to the control groups. However, most of these trials may be at a high risk of bias. Thus, there is still not enough evidence to stipulate which combinations are the...
Circulatory and Placental Expression of Soluble Fms-like Tyrosine Kinase-1 and Placental Growth Factor in HIV-infected Preeclampsia
Source : https://www.eurekaselect.com/article/127943
Background: An imbalance between angiogenic and anti-angiogenic factors plays a fundamental role in the pathogenesis of preeclampsia (PE). Studies have shown a dysregulation of sFlt-1 and placental growth factor (PlGF)...
Conclusion: The angiogenic imbalance evident in the circulatory system by higher sFlt-1 compared to PlGF levels is replicated in the placenta by reduced expression of PlGF receptors in comparison to sFlt-1 receptors. However, there is a lack of data that explore the relationship between HAART and anti-angiogenic factors in the placenta and the...
Fostemsavir and ethinyl estradiol drug interaction: Clinical recommendations for co-administration - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36372442/
Applying the results of Study 206279 and other relevant ARV-contraceptive studies, we recommend that when co-administering fostemsavir with combined oral contraceptives (COCs) and other oestrogen-based therapies, EE dose should not...
Conclusions: Applying the results of Study 206279 and other relevant ARV-contraceptive studies, we recommend that when co-administering fostemsavir with combined oral contraceptives (COCs) and other oestrogen-based therapies, EE dose should not exceed 30 μg or equivalent, and caution is advised in the case of individuals with risk factors for...